Article in Microorganisms, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors.
Maria Cristina Ferreira de SousaInstitute of Parasitology, Vetsuisse Faculty, University of Bern, 3012 Bern, Switzerland.ORCID 0009-0007-2056-2157
Joachim MüllerInstitute of Parasitology, Vetsuisse Faculty, University of Bern, 3012 Bern, Switzerland.ORCID 0000-0001-8189-9270
Manfred HellerProteomics and Mass Spectrometry Core Facility, Department for BioMedical Research (DBMR), University of Bern, 3012 Bern, Switzerland.ORCID 0000-0002-6364-7325
Anne-Christine UldryProteomics and Mass Spectrometry Core Facility, Department for BioMedical Research (DBMR), University of Bern, 3012 Bern, Switzerland.
Sophie Braga-LagacheProteomics and Mass Spectrometry Core Facility, Department for BioMedical Research (DBMR), University of Bern, 3012 Bern, Switzerland.
Kayode K OjoDepartment of Medicine, Center for Emerging and Re-Emerging Infectious Diseases, University of Washington, Seattle, WA 98109-4766, USA.
Wesley C Van VoorhisDepartment of Medicine, Center for Emerging and Re-Emerging Infectious Diseases, University of Washington, Seattle, WA 98109-4766, USA.
Andrew HemphillInstitute of Parasitology, Vetsuisse Faculty, University of Bern, 3012 Bern, Switzerland.ORCID 0000-0002-0622-2128
Funding
Bumped-Kinase Inhibitor Drug Development for ToxoplasmosisR01HD102487 · NICHD · UNIVERSITY OF WASHINGTON · PI VAN VOORHIS, WESLEY C · 2021 to 2025
$3.3M
Clinical Research Training in Infectious DiseasesT32AI055412 · NIAID · TUFTS MEDICAL CENTER · PI SNYDMAN, DAVID RICHARD · 2005 to 2014
$1.3M
National Institutes of Health (NIH) R01AI55412National Institutes of Health (NIH) R01HD102487NIAID NIH HHS T32 AI055412NICHD NIH HHS R01 HD102487Swiss National Science Foundation 310030_214897
6 · The paper itself
Abstract
Bumped kinase inhibitor 1708 (BKI-1708), previously demonstrated to target apicomplexan kinases and CDPK1 and MAPKL1, exhibits remarkable activity against
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Affino-Proteomic Analysis of Bumped Kinase Inhibitor BKI-1708 in · full record | OpenQuestion